Literature DB >> 2372654

The effects of cholecystokinin octapeptide on human isolated alimentary muscle.

M D'Amato1, I F Stamford, A Bennett.   

Abstract

1. We studied cholecystokinin octapeptide (CCK-OP) for its motor effects and sites of action on human isolated muscle from stomach, small intestine and colon. 2. CCK-OP induced a concentration-dependent contraction of all the longitudinal muscles and of circular muscle from the stomach and large intestine. The peptide acted directly on these muscles at a site not involving muscarinic receptors. 3. CCK-OP relaxed the circular muscle of the small intestine and/or reduced the contractions to acetylcholine, by stimulating intramural postganglionic inhibitory neurones.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2372654      PMCID： PMC1917477          DOI： 10.1111/j.1476-5381.1990.tb12063.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  22 in total

1.  Relationship between in-vitro studies of gastrointestinal muscle and motility of the alimentary tract in vivo.

Authors:  A Bennett
Journal:  Am J Dig Dis       Date:  1968-05

2.  Motor responses of the sigmoid colon and rectum to exogenous cholecystokinin and secretin.

Authors:  V P Dinoso; H Meshkinpour; S H Lorber; J G Gutierrez; W Y Chey
Journal:  Gastroenterology       Date:  1973-09       Impact factor: 22.682

3.  Evidence that acetylcholine released by gastrin and related polypeptides contributes to their effect on gastrointestinal motility.

Authors:  S E Vizi; G Bertaccini; M Impicciatore; J Knoll
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

4.  Comparison of effects of gastrin, cholecystokinin-pancreozymin, secretin, and glucagon on human stomach muscle in vitro.

Authors:  A J Cameron; S F Phillips; W H Summerskill
Journal:  Gastroenterology       Date:  1970-10       Impact factor: 22.682

5.  Inhibition of the action of cholecystokinin octapeptide on the guinea pig ileum myenteric plexus by dibutyryl cyclic guanosine monophosphate.

Authors:  J B Hutchison; G J Dockray
Journal:  Brain Res       Date:  1980-12-08       Impact factor: 3.252

6.  The role of local cholinergic pathways in the motor response to cholecystokinin and gastrin in isolated guinea-pig fundus and antrum.

Authors:  T Gerner; J F Haffner
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

7.  Effect of cholecystokinin and the octapeptide of cholecystokinin on the feline sphincter of Oddi and gallbladder. Mechanisms of action.

Authors:  J Behar; P Biancani
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

8.  Electrical and mechanical effects of molecular variants of CCK on antral smooth muscle.

Authors:  K G Morgan; P F Schmalz; V L Go; J H Szurszewski
Journal:  Am J Physiol       Date:  1978-09

9.  Evidence that the action of cholecystokinin octapeptide on the guinea pig ileum longitudinal muscle is mediated in part by substance P release from the myenteric plexus.

Authors:  J B Hutchison; G J Dockray
Journal:  Eur J Pharmacol       Date:  1981-01-05       Impact factor: 4.432

10.  The effect of cholecystokinin on human taenia coli.

Authors:  E H Egberts; A G Johnson
Journal:  Digestion       Date:  1977       Impact factor: 3.216
View more
  3 in total

1.  Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.

Authors:  M D'Amato; I F Stamford; A Bennett
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

Review 2.  Involvement of endogenous CCK and CCK1 receptors in colonic motor function.

Authors:  Gábor Varga; András Bálint; Beáta Burghardt; Massimo D'Amato
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 3.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.